Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98


NF1 mutations identify molecular and clinical subtypes of lung adenocarcinomas.

Tlemsani C, Pécuchet N, Gruber A, Laurendeau I, Danel C, Riquet M, Le Pimpec-Barthes F, Fabre E, Mansuet-Lupo A, Damotte D, Alifano M, Luscan A, Rousseau B, Vidaud D, Varin J, Parfait B, Bieche I, Leroy K, Laurent-Puig P, Terris B, Blons H, Vidaud M, Pasmant E.

Cancer Med. 2019 Jun 14. doi: 10.1002/cam4.2175. [Epub ahead of print]


Frequency and clinical significance of NF1 mutation in lung adenocarcinomas from East Asian patients.

Pan Y, Yuan C, Cheng C, Zhang Y, Ma Y, Zheng D, Zheng S, Li Y, Jin Y, Sun Y, Chen H.

Int J Cancer. 2019 Jan 15;144(2):290-296. doi: 10.1002/ijc.31871. Epub 2018 Nov 4.


Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.

Redig AJ, Capelletti M, Dahlberg SE, Sholl LM, Mach S, Fontes C, Shi Y, Chalasani P, Jänne PA.

Clin Cancer Res. 2016 Jul 1;22(13):3148-56. doi: 10.1158/1078-0432.CCR-15-2377. Epub 2016 Feb 9.


Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.

Cosgarea I, Ugurel S, Sucker A, Livingstone E, Zimmer L, Ziemer M, Utikal J, Mohr P, Pfeiffer C, Pföhler C, Hillen U, Horn S, Schadendorf D, Griewank KG, Roesch A.

Oncotarget. 2017 Jun 20;8(25):40683-40692. doi: 10.18632/oncotarget.16542.


Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.

Mackenzie R, Kommoss S, Winterhoff BJ, Kipp BR, Garcia JJ, Voss J, Halling K, Karnezis A, Senz J, Yang W, Prigge ES, Reuschenbach M, Doeberitz MV, Gilks BC, Huntsman DG, Bakkum-Gamez J, McAlpine JN, Anglesio MS.

BMC Cancer. 2015 May 19;15:415. doi: 10.1186/s12885-015-1421-8.


Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.

Shim HS, Kenudson M, Zheng Z, Liebers M, Cha YJ, Hoang Ho Q, Onozato M, Phi Le L, Heist RS, Iafrate AJ.

J Thorac Oncol. 2015 Aug;10(8):1156-62. doi: 10.1097/JTO.0000000000000579.


Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations.

Sangha N, Wu R, Kuick R, Powers S, Mu D, Fiander D, Yuen K, Katabuchi H, Tashiro H, Fearon ER, Cho KR.

Neoplasia. 2008 Dec;10(12):1362-72, following 1372.


Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.

Cortot AB, Younes M, Martel-Planche G, Guibert B, Isaac S, Souquet PJ, Commo F, Girard P, Fouret P, Brambilla E, Hainaut P, Soria JC.

Clin Lung Cancer. 2014 Mar;15(2):124-30. doi: 10.1016/j.cllc.2013.08.003. Epub 2013 Oct 26.


Mutation Profile of Resected EGFR-Mutated Lung Adenocarcinoma by Next-Generation Sequencing.

Zhao ZR, Lin YB, Ng CSH, Zhang R, Wu X, Ou Q, Chen W, Zhou WJ, Lin YB, Su XD, Shao YW, Long H.

Oncologist. 2019 Mar 14. pii: theoncologist.2018-0567. doi: 10.1634/theoncologist.2018-0567. [Epub ahead of print]


Frequency of well-identified oncogenic driver mutations in lung adenocarcinoma of smokers varies with histological subtypes and graduated smoking dose.

Li H, Pan Y, Li Y, Li C, Wang R, Hu H, Zhang Y, Ye T, Wang L, Shen L, Sun Y, Chen H.

Lung Cancer. 2013 Jan;79(1):8-13. doi: 10.1016/j.lungcan.2012.09.018. Epub 2012 Oct 23.


RASA1 and NF1 are Preferentially Co-Mutated and Define A Distinct Genetic Subset of Smoking-Associated Non-Small Cell Lung Carcinomas Sensitive to MEK Inhibition.

Hayashi T, Desmeules P, Smith RS, Drilon A, Somwar R, Ladanyi M.

Clin Cancer Res. 2018 Mar 15;24(6):1436-1447. doi: 10.1158/1078-0432.CCR-17-2343. Epub 2017 Nov 10.


Next‑generation sequencing‑based detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her‑2 and TP53 mutations in patients with non‑small cell lung cancer.

Jing C, Mao X, Wang Z, Sun K, Ma R, Wu J, Cao H.

Mol Med Rep. 2018 Aug;18(2):2191-2197. doi: 10.3892/mmr.2018.9210. Epub 2018 Jun 22.


The NF1 somatic mutational landscape in sporadic human cancers.

Philpott C, Tovell H, Frayling IM, Cooper DN, Upadhyaya M.

Hum Genomics. 2017 Jun 21;11(1):13. doi: 10.1186/s40246-017-0109-3. Review.


Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing.

Shajani-Yi Z, de Abreu FB, Peterson JD, Tsongalis GJ.

Neoplasia. 2018 Mar;20(3):256-262. doi: 10.1016/j.neo.2017.12.005. Epub 2018 Feb 16.


Frequency of driver mutations in lung adenocarcinoma from female never-smokers varies with histologic subtypes and age at diagnosis.

Zhang Y, Sun Y, Pan Y, Li C, Shen L, Li Y, Luo X, Ye T, Wang R, Hu H, Li H, Wang L, Pao W, Chen H.

Clin Cancer Res. 2012 Apr 1;18(7):1947-53. doi: 10.1158/1078-0432.CCR-11-2511. Epub 2012 Feb 8.


Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine.

Hou H, Liu D, Zhang C, Jiang Y, Lu G, Zhou N, Yang X, Zhang X, Li Z, Zhu H, Qian Z, Zhang X.

Oncotarget. 2017 Sep 27;8(62):105072-105080. doi: 10.18632/oncotarget.21349. eCollection 2017 Dec 1.


[Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].

Liu B, Shi SS, Wang X, Xu Y, Zhang XH, Yu B, Lu ZF, Wang JD, Zhou XJ.

Zhonghua Bing Li Xue Za Zhi. 2012 Aug;41(8):505-10. doi: 10.3760/cma.j.issn.0529-5807.2012.08.001. Chinese.


Mutation burden and other molecular markers of prognosis in colorectal cancer treated with curative intent: results from the QUASAR 2 clinical trial and an Australian community-based series.

Domingo E, Camps C, Kaisaki PJ, Parsons MJ, Mouradov D, Pentony MM, Makino S, Palmieri M, Ward RL, Hawkins NJ, Gibbs P, Askautrud H, Oukrif D, Wang H, Wood J, Tomlinson E, Bark Y, Kaur K, Johnstone EC, Palles C, Church DN, Novelli M, Danielsen HE, Sherlock J, Kerr D, Kerr R, Sieber O, Taylor JC, Tomlinson I.

Lancet Gastroenterol Hepatol. 2018 Sep;3(9):635-643. doi: 10.1016/S2468-1253(18)30117-1. Epub 2018 Jul 2.


Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.

Latteyer S, Tiedje V, König K, Ting S, Heukamp LC, Meder L, Schmid KW, Führer D, Moeller LC.

Endocrine. 2016 Dec;54(3):733-741. doi: 10.1007/s12020-016-1080-9. Epub 2016 Oct 1.


Mapping of actionable mutations to histological subtype domains in lung adenocarcinoma: implications for precision medicine.

Wright GM, Do H, Weiss J, Alam NZ, Rathi V, Walkiewicz M, John T, Russell PA, Dobrovic A.

Oncotarget. 2014 Apr 30;5(8):2107-15.

Supplemental Content

Support Center